UNITED STATES

SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORTPursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2021

ABBVIE INC. (Exact Name of Registrant as Specified in its Charter)

_______________________________________________

Delaware 001-35565 32-0375147(State or other Jurisdiction

of Incorporation) (Commission File Number) (IRS Employer

Identification No.)_______________________________________________

1 North Waukegan Road

North Chicago, Illinois 60064-6400(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.500% Senior Notes due 2021 ABBV21C New York Stock Exchange1.500% Senior Notes due 2023 ABBV23B New York Stock Exchange1.375% Senior Notes due 2024 ABBV24 New York Stock Exchange1.250% Senior Notes due 2024 ABBV24B New York Stock Exchange0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange2.625% Senior Notes due 2028 ABBV28B New York Stock Exchange2.125% Senior Notes due 2029 ABBV29 New York Stock Exchange1.250% Senior Notes due 2031 ABBV31 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure. On January 12, 2021, AbbVie Inc. posted an investor presentation to its website at: https://investors.abbvie.com/presentations. A copy is attached as Exhibit 99.1 to thisCurrent Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” forpurposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference in any filing under the SecuritiesAct of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Additionally, the submission of the information set forth in thisItem 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by RegulationFD. Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo. Exhibit

99.1 Investor Presentation dated January 12, 2021.104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized. ABBVIE INC. Date: January 12, 2021 By: /s/ Robert A. Michael Name: Robert A. Michael Title: Executive Vice President, Chief Financial Officer

3

Exhibit 99.1

rgan Healthcare Conference RichardGonzalez Chairman and ChiefExecutive Officer January 12, 2021

Forward-Looking Statements and Non-GAAP Financial information Somestatements in this presentation are, ormay be considered, forward-lookingstatements for purposes of the PrivateSecurities Litigation Reform Act of1995. The words "believe," "expect,""anticipate," "project" and similarexpressions, among others, generallyidentify forward-looking statements.AbbVie cautions that these forward-looking statements are subject to risksand uncertainties that may cause actualresults to differ materially from thoseindicated in the forward-lookingstatements. Such risks and uncertaintiesinclude, but are not limited to, thefailure to realize the expected benefitsof AbbVie’s acquisition of Allergan orto promptly and effectively integrateAllergan’s business, challenges tointellectual property, competition fromother products, difficulties inherent inthe research and development process,adverse litigation or government action,and changes to laws and regulationsapplicable to our industry. Additionalinformation about the economic,competitive, governmental,technological and other factors that mayaffect AbbVie's operations is set forth inItem 1A, "Risk Factors," of AbbVie's2019 Annual Report on Form 10-K,which has been filed with the Securitiesand Exchange Commission, as updatedby its Quarterly Reports on Form 10-Qand in other documents that AbbViesubsequently files with the Securitiesand Exchange Commission that update,supplement or supersede suchinformation. AbbVie undertakes noobligation to release publicly anyrevisions to forward-looking statementsas a result of subsequent events ordevelopments, except as required bylaw. This presentation contains GAAPand certain non-GAAP financialmeasures. Non-GAAP financialmeasures are adjusted for certain non-cash items and for factors that areunusual or unpredictable, and excludethose costs, expenses and otherspecified items presented in AbbVie’sreconciliation tables. AbbVie’smanagement believes non-GAAPfinancial measures provide usefulinformation to investors regardingAbbVie’s results of operations and assistmanagement, analysts and investors inevaluating the performance of thebusiness. Non-GAAP financialmeasures should be considered inaddition to, and not as a substitute for,measures of financial performanceprepared in accordance with GAAP.Reconciliations of these non-GAAPfinancial measures to the mostcomparable GAAP measures areavailable in the appendix to thispresentation and on the company’swebsite at www.abbvieinvestor.com.Today’s discussions and presentation areintended for the investor communityonly; materials are not intended topromote the products referenced hereinor otherwise influence healthcareprescribing decisions.

AbbVie is a DiversifiedBiopharmaceutical Company Well-Positioned for Sustainable GrowthStrong Leadership Positions inAttractive Growth MarketsImmunologyHematologic OncologyNeuroscienceAllergan Aesthetics

Broad Portfolio and Pipeline ofAttractive, Durable Growth AssetsLarge, Diverse On-Market Portfolio andRobust Pipeline of Novel TherapiesWill Drive Return to Revenue Growthin 2024 Continued strong top-linegrowth expected leading up to U.S.Humira LOE event in 2023 Expect totalcompany sales to decline in 2023following U.S. Humira LOE Quicklyreturn to growth following U.S. HumiraLOE, with modest top-line growthexpected in 2024 Expect rapid return tostrong top-line growth in 2025, withhigh-single digit CAGR throughremainder of decade

Compelling Capital AllocationPhilosophy, Balanced BetweenSupporting Growth and ReturningCapital to Shareholders Strongoperating cash flow to supportinvestments for growth, return of cash toshareholders and rapid debt repaymentContinued R&D investment inpromising, innovative science acrosseach of our therapeutic categories, aswell as capacity to pursue additionalmid-to-late stage pipeline assets toaugment the internal pipeline Supports arobust and growing dividend

Consistently Delivered Top-TierPerformance Met or Exceeded KeyFinancial Goals Since BecomingIndependent Company Adjusted NetRevenue +13.5% +18.8% DeliveredTop-Tier Shareholder Return TotalShareholder Return Since Inception***+342% Since Inception +225% Increasein Quarterly Dividend Since Inceptionin 2013** *Based on midpoint of 2020revenue and adjusted EPS guidanceprovided on 3Q20 earnings call.**Based on company’s quarterly cashdividend ($1.30 per share) beginningwith the dividend payable on February16, 2021 to shareholders of record as ofJanuary 15, 2021. ***Total shareholderreturn January 1, 2013 through January11, 2021.

Best-in-Class Medicines and InnovativePipeline Position AbbVie for SustainedLeadership in Immunology CurrentlyApprovedUnder Regulatory ReviewEarly-Stage Immunology ProgramsFocused on Novel Therapies to ImproveClinical Performance AcrossRheumatology, Dermatology andGastroenterology

Adding new indications in 2021-2025timeframe and ramping to peak share2025-2030, both Rinvoq and Skyriziexpected to peak in early 2030s Basedon the launch trajectory in their initialindications and the robust Phase 3 datain >$15.0B Expected Combined Risk-Adjusted Global Sales $1B IBD $1Bfollow-on indications, we now expectcombined risk-adjusted global sales of>$15 billion for Rinvoq and Skyrizi in2025 International markets expected tocontribute nearly $4 billion in risk-adjusted sales in 2025 Skyrizi >$7.0B$1.5B IBD $5.5B PsO & PsA SpA $2BAD Rinvoq >$8.0B

First-in-class BTK inhibitor hastransformed treatment paradigm; Goldstandard in CLL and the preferredtreatment for MCL and WM Mostcomprehensive efficacy and safety datain the BTK inhibitor class, with sixpositive Phase 3 CLL studiesdemonstrating superiority over allstandard-of-care chemotherapy-basedregimens First-in-class Bcl-2 inhibitorwith 5 FDA Breakthrough Therapydesignations and 4 approved indicationsacross CLL and AML populationsPotential to become a foundationaltherapy in multiple hematologicmalignancies, allowing patients toachieve more durable, deeper responses,including the option for some patients tostop treatment Approved Indication InPh3 Development

Apoptosis & Regulated Cell DeathTumor Targeting Novel Immuno-Oncology First and best-in-class assetsin apoptosis that will expand into solidtumors Superior bispecifics andconjugates for both heme and solidtumors Novel assets that restore T-cellkilling activity in the tumormicroenvironment

$5 Billion Portfolio with Opportunityfor Significant Growth MigrainePsychiatry Market leading migraineportfolio with options for every patientacross the migraine spectrum BotoxTherapeutic approved for chronicmigraine prevention Ubrelvy approvedfor acute treatment of migraine attacksAtogepant recently completed Phase 3for episodic migraine prevention Aspirefor industry leadership in mood, anxietyand thought disorders with high unmetneed Vraylar approved forschizophrenia, bipolar I disorder, bipolardepression Vraylar nearing completionof Phase 3 in adjunctive majordepressive disorder Neuro-DegenerationNeuro-Rehabilitation/ProtectionAdvance a transformative pipeline forAlzheimer’s and Parkinson’s diseasesDuopa approved and ABBV-951nearing completion of registrationaltrials in advanced PD ABBV-8E12,AL002, AL003 & ABBV-0805 in early-stage development for AD and PDdisease modification Sustain leadershipin spasticity & movement disorders andexplore neuro-restoration approaches inMS, Stroke, SCI Botox Therapeuticapproved in spasticity and certainmovement disorders Elezanumab inearly-stage development for MS, strokeand spinal cord injury

Building a Leading Portfolio withOptions for Every Patient Across theMigraine Spectrum 1-3 Migraine Days /Month 14.1M patients 4-7 MigraineDays 8.5M patients 8-14 Migraine Days5.6M patients 15+ Days 3.3M patientsPrevention Therapies Acute TreatmentAtogepant Acute Migraine TreatmentMarket dominated by triptans, but ~40%of patients discontinue due to lack ofefficacy and ~25% discontinue use dueto side effects $1Bn market in the U.S.today, expected to growth to $3Bn by2025 Based on competitive profile andstrong launch, we believe Ubrelvyrepresents a $1Bn+ peak salesopportunity Prevention Treatment forMigraine Migraine prevention market inthe U.S. estimated at ~$2Bn today,expected to grow to nearly $6Bn by2025 Episodic Migraine (fewer than 15migraine days per month) represents~90% of the market, with the moredebilitating Chronic Migraine (15 ormore migraine days per month)representing 10% Botox Therapeutic isa unique foundational preventiontreatment for people living with chronicmigraine and expect to remain animportant treatment option despite newcompetition As an efficacious oraloption with favorable side effect andsafety profile, we believe atogepant willbe a competitive agent in episodicmigraine and has the potential toprovide $1Bn+ in peak sales AtogepantNot for promotional use J.P. MorganHealthcare Conference | January 12,2021 12

Vraylar provides strong efficacy acrossmultiple symptoms, with minimalimpact on weight, lipids and fastingblood glucose Atypical antipsychoticsthat treat multiple symptoms receive agreater share of the atypical marketBrandedGenerics Approved AdultIndications ✓✓✓ Bipolar Ph3Adjunctive MDD Ongoing✓✓✓ MarketShare12%<1%<1%4%2%<1%36%21%16%3%13%3% ExpectVraylar Peak Sales to Approach $4Billion with Current ApprovedIndications Market share figures includeall brands in a given family. Source:IQVIA; Evaluate pharma; AbbVieestimates.

Leadership Positions in the U.S. AcrossAll Areas #1#1#1#1#1 66% MarketShare 46% Market Share 67% MarketShare 54% Market Share 51% MarketShare New Product Introduction, GlobalExpansion and Increasing PenetrationWill Drive Significant Growth forAesthetics Business

Developing Innovative Procedures toDrive Advancement of AestheticsMedicine Advance and AcceleratePipeline Drive Next-GenerationTechnologies Lead Industry in DigitalTechnologies Indication Expansion: 10active programs across on-marketfranchises Geographic Expansion:Expanding global footprint to bringdevelopment programs to major globalmarkets Business Development:Strengthening our core franchises andaddressing areas of unmet need Toxins:Developing a portfolio of novelneurotoxins and improved formulationsFillers: Developing bio-stimulatory andregenerative fillers with improvedperformance properties BodyContouring: Building platforms toreduce treatment time and address areasof highest unmet need Developinginnovative digital endpoints using AIand machine learning for morepredictable assessments in clinical trialsEnabling clinical grade remoteimage/video capture to provide apatient-centric format and move towardsvirtual clinical trials Developingscientifically valid assessments ofchanges in skin biology and skin qualityby leveraging the latest technologicaladvancements Enhancing digitalproducts and services for patients andprovider through Allē platform AllerganAesthetics has a Broad Pipeline WithMore Than 35 Active Programs

AbbVie R&D Pipeline As of January12, 2021 Phase 1Phase 2Registrational /Phase 3Submitted *Pivotal studyplanning in progress for HArmonyCA inU.S. Immunology Oncology ■ ABBV-157 (RORgT) PsO ■ ABBV-154 (TNF-Steroid ADC) RA ■ Rinvoq (JAK 1)CD Rinvoq (JAK 1) PsA ■ ABBV-022(IL-22) UC ■ Rinvoq (JAK 1) HS ■Rinvoq (JAK 1) UC Rinvoq (JAK 1)AD ■ ABBV-151 (GARP+TGFb1)Solid Tumors ■ Skyrizi (IL-23) HS ■Rinvoq (JAK 1) GCA Rinvoq (JAK 1)AS ■ ABBV-155 (BCL-xL ADC) SolidTumors ■ ABBV-599 (BTK/JAK) SLE■ Rinvoq (JAK 1) nr-Axial SpA ■ABBV-181 (PD-1) Solid Tumors ■Ravagalimab (CD40) UC ■ Skyrizi (IL-23) CD ■ ABBV-184 (Survivin-CD3)AML, NSCLC ■ ALPN-101(ICOS/CD28) SLE ■ Skyrizi (IL-23)UC ■ ABBV-368 (OX40) Solid Tumors■ Teliso-V (cMet ADC) NSCLC ■Skyrizi (IL-23) PsA ■ ABBV-467(MCL) Heme Tumors ■ Solid/HemeTumors ■ Imbruvica (BTK) 1L FL ■ABBV-621 (TRAIL) Solid/HemeTumors ■ ABBV-8E12 (Tau) AD ■Imbruvica (BTK) 1L MCL ■ ABBV-744 (BET) AML, MF ■ Elezanumab(RGMa) MS ■ Imbruvica (BTK) R/RMCL ■ Mivebresib (BET) MF ■Elezanumab (RGMa) Stroke ■Imbruvica (BTK) R/R FL/MZL ■ABBV-927 (CD40) Solid Tumors ■Elezanumab (RGMa) SCI ■ Imbruvica(BTK) 1L CLL ■ ABBV-647 (PTK7ADC) NSCLC ■ AL002 (TREM2) AD■ Venclexta (BCL-2) 1L CLL ■ ABBV-011 (SEZ6 ADC) SCLC ■ BoNTE(SNARE) Glabellar Lines ■ Venclexta(BCL-2) AML Maintenance ■Venclexta (Bcl-2) ALL ■ Botox(SNARE) Platysma Prominence ■Venclexta (BCL-2) R/R MM t(11;14) ■CCW702 (CD3-PSMA) Prostate Cancer■ Abicipar (VEGF-A) DME ■Venclexta (BCL-2): MDS ■CLBR001/SWI019 (sCAR-T) HemeTumors ■ Armour Thyroid (T3T4)Hypothyroidism ■ Navitoclax (BCL-2/BCL-xL) Myelofibrosis ■ GEN1044(CD3x5T4) Solid Tumors ■ AGN-151607 (SNARE) Afib ■ Epcoritamab(CD3xCD20): R/R DLBCL ■ GEN3009(CD37) Heme Tumors ■ Veliparib(PARP) BRCA Breast Cancer ■ JAB-3068 / JAB-3312 (SHP2) Solid Tumors■ Veliparib (PARP) 1L Ovarian Cancer■ HPN-217 (CD3-BCMA) MM ■ABBV-951 (dopamine receptor) PD ■TNB-383B (CD3-BCMA) MM ■Atogepant (CGRP) MigraineProphylaxis ■ TTX-030 (CD39) SolidTumors ■ Vraylar (D2,5-HT1A, 5-HT2A) aMDD ■ ABBV-IMAB-TJC4(CD47) Heme/Solid Tumors ■ Botox(SNARE) Masseter Prominence ■ABBV-0805 (a-Synuclein) PD ■NivobotulinumtoxinA (SNARE) FacialLines ■ AL003 (CD33) AD ■HArmonyCa (HA-CaHA) DermalFiller* ■ AGN-231868 (Chemokine)Dry Eye ■ AGN-190584 (Muscarinic)Presbyopia ■ ■ AGN-242428 (RoRg)Dry Eye ■ Elagolix + Hormonal Add-Back (GnRH) EM ■ ■ AGN-241622(Alpha2) Presbyopia ■Aztreonam/Avibactam (PBP3) Infection■ ABBV-4083 (TylAMac) FilarialDiseases ■ CF Triple Combo (CFTR-C1/CFTR-C2/CFTR-P) ■ ■ ABBV-1882 HIV ■ Aesthetics Eye CareTargeted Investment

Anticipated Key Pipeline Events

AbbVie: A Unique InvestmentOpportunity Poised for ContinuedStrong Shareholder Returns Portfolio ofleading brands in attractive andsustainable markets Pipeline ofinnovative, highly differentiated assetsto address significant unmet needs, withpotential to drive significant growthCompelling capital allocationphilosophy balanced, betweensupporting growth and returning capitalto shareholders Track record of strongexecution, consistently meeting orexceeding financial commitments todeliver industry leading financialperformance A unique investmentvehicle, offering top-tier revenue andEPS growth, significant cash flow andstrong return of capital to shareholders

[LOGO]

GAAP to Non-GAAP Reconciliations Diluted earningsper share 20132014201520162017201820192020E Asreported(GAAP)$2.56$1.10$3.13$3.63$3.30$3.66$5.28$3.90Adjusted for specified items:Other0.040.050.130.220.310.31(0.58)(0.10) Asadjusted (non-GAAP)$3.14$3.32$4.29$4.82$5.60$7.91$8.94$10.48Acquisition related costs primarily include intangibleasset amortization, changes in the fair value ofcontingent consideration, and transaction, financing,and integration costs associated with acquisitions aswell as amortization of acquisition date fair value step-up for inventory. Separation costs are expenses relatedto the separation of AbbVie from Abbott. Acquired in-process R&D, milestones and other R&D expensesprimarily consist of upfront and milestone paymentsassociated with R&D collaborations and licensingarrangements. Other primarily includes charges andresolutions of litigation matters, restructuring chargesassociated with streamlining global operations, taxaudit settlements, charitable contributions, and theReata divestiture. Net revenues Adjusted net revenuesexclude other revenue of $81 million in 2014, $40million in 2015, $78 million in 2016, $20 million in2018 and $20 million in 2020. Other revenue primarilyrepresents collaboration milestone revenue and priorperiod royalty revenue. Note: 2020E reflects thecompany’s current guidance as of the date of thispresentation.

AbbVie’s Partnered Assets Skyrizideveloped in cooperation withBoehringer Ingelheim Imbruvica jointlydeveloped and commercialized withJanssen Biotech Venclexta developed byAbbVie and Roche, commercialized byAbbVie and Genentech, a member ofthe Roche Group Epcoritamab,GEN1044 and GEN3009 jointlydeveloped with Genmab Elagolixdeveloped in cooperation withNeurocrine Biosciences ALPN-101developed by Alpine through Phase 2and AbbVie holds option for additionaldevelopment and commercializationABBV-CX-2029 developed incooperation with CytomX TherapeuticsABBV-8E12 developed in cooperationwith C2N Diagnostics AL002/AL003developed by Alector through Phase 2and AbbVie holds option for additionaldevelopment and commercializationABBV-157 developed in cooperationwith Inventiva ABBV-151 developed incooperation with Argenx ABBV-621(Eftoza) developed in cooperation withApogenix ABBV-647 developed incooperation with Pfizer CCW702 /CLBR001 / SWI019 developed byCalibr in a first-in-patient trial andAbbVie holds option to license theprogram JAB-3068 / JAB-3312developed in cooperation with JacobioHPN-217 developed by Harpoonthrough Phase 1/2 and AbbVie holdsoption for additional development andcommercialization TNB-383Bdeveloped by TeneoOne through Phase1 and AbbVie holds exclusive right toacquire TeneoOne TTX-030 developedby Trishula Therapeutics through Phase1b and AbbVie has option to lead globaldevelopment and commercializationABBV-IMAB-TJC4 (CD47) developedin cooperation with I-Mab ABBV-0805developed in cooperation withBioArctic